Alzamend Neuro, Inc. (NASDAQ:ALZN) made waves Tuesday when the company announced its decision to terminate its “at-the-market ...

(Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease ("Alzheimer’s"), bipolar disorder ("BD"), major ...

The Dow Jones index closed higher by over 250 points on Tuesday. When insiders purchase or sell shares, it indicates their ...

Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Alzamend Neuro, a developer of treatments for neurodegenerative diseases and psychiatric disorders, soared in its first trading day after its IPO. Alzamend Neuro ALZN, a developer of treatments ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ascendiant analyst Edward Woo maintained a Buy rating on Alzamend Neuro (ALZN – Research Report) yesterday and set a price target of $21.00. Edward Woo has given his Buy rating due to a ...

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...